Banyu To Conduct Major Marketing Restructuring; Considers Job Cuts
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Merck's Japanese subsidiary Banyu Pharmaceutical said Sept. 17 that it will streamline its marketing structure and consolidate its branches and business offices into 20 locations and assign sales staff to sell drugs by illness, instead of the industry tradition of regional sales
You may also be interested in...
Banyu to Close Tsukuba Lab as Part of Merck’s Global Research Revamp
TOKYO - Merck subsidiary Banyu Pharmaceutical, said Oct. 23 it would close its research laboratory in Tsukuba City, northeast of Tokyo, by the end of 2009, leaving only a fraction of foreign drug makers with basic research activities in Japan
Banyu to Close Tsukuba Lab as Part of Merck’s Global Research Revamp
TOKYO - Merck subsidiary Banyu Pharmaceutical, said Oct. 23 it would close its research laboratory in Tsukuba City, northeast of Tokyo, by the end of 2009, leaving only a fraction of foreign drug makers with basic research activities in Japan
MHLW Lifts Conditions On Banyu's Hyperlipidemia Drug Lipovas
The first section on drugs of the Pharmaceutical Affairs and Food Sanitation Council at the Ministry of Health, Labor and Welfare lifted conditions on Banyu Pharmaceutical's hyperlipidemia drug Lipovas (simvastatin). Imposed upon approval in 2001, the conditions required Banyu to study the relationship between increased dosage and the onset of rhabdomyolysis, but no cases of rhabdomyolysis have been reported and creatine kinase counts, directly related to the disease, are lower after market launch compared to those reported in clinic trials. (Click here for more - Japanese language)